SKU: G61RHA20
SAADAVUS: Varud madalaima väärtusega turul
TARNIMINE: Sarnased päevased kaubatellimused varem kui 14
H00SIZE: 20 eksamit/komplekt SPECIFICITY: 98,90%
Sorteeri
Immunokromatograafia kiire kontroll
Kirjeldus
Külgliikumise immunokromatograafiline test, mis võttis kasutusele kaksikvärvisüsteemi.
SARS-CoV-2 antigeeni kvalitatiivseks tuvastamiseks ninaneelu tampooniproovist.
Kontroll sisaldab kolloidkullaga konjugaatpadja ja membraaniriba, mis on eelnevalt kaetud kontrolljälgedel (T) olevate SARS-CoV-2 antigeeni spetsiifiliste antikehadega.
Kontrolljälgedel tundub visuaalselt must riba (antikeha-antigeeni-antikeha kuldkonjugaat on keeruline) (T) Kui proovis on SARS-CoV-2 antigeen.
Juhtimisliin (C) näitab, et kontroll viiakse läbi nõuetekohaselt.
Hinnatud paneeliprooviga (n = 75) PCR järgi
Tundlikkus: 90,2 %
Spetsiifilisus: 100 %
VITROS SARS CoV2 antigeeni CLIA juhtimine, mis põhineb peamiselt Ortho Medicali kontrollil
Diagnostika
1. VITROS SARS CoV2 antigeeni test on kemoluminestseeruv immuunanalüüs, mis on ette nähtud
SARS-CoV-2 nukleokapsiidi antigeenide kvalitatiivseks tuvastamiseks nina-neelu (NP) proovides inimestelt, kellel
kahtlustatakse COVID-19 ühe kuni viie päeva jooksul pärast sümptomite ilmnemist. või
asümptomaatilistelt inimestelt kogutud turba keskel olevad isendid .
2. Analüüs tuleks läbi viia VITROS 3600 immunodiagnostikasüsteemis või VITROS 5600 / VITROS XT 7600
sisseehitatud süsteemis firmalt Ortho.
Funktsioonid
COVID-19, ninaneelu tampoonid
Kalibreerimisviis
Kvalitatiivne
VITROS SARS CoV2 antigeeni test – protseduurilised sammud: –
1. etapp: Ninaneelu tampooniproovide valik:
1. Hankige ninaneelu tampooniproov, sisestades steriilse tampooni ninasõõrmesse.
2. Lükake steriilset tampooni, kuni turbinaadi laval tekib takistus.
3. Pöörake steriilset tampooni mitu korda nina -neelu seina poole ja minge
10 sekundiks sellesse kohta, et tampooni otsik küllastuks.
4. Võtke tampoon kiiresti ninasõõrmelt ära.
5. Asetage tampooniproov viirustranspordi puhvertuubi ja sulgege toru tihedalt.
6. Viige tampoonimuster VTM -is jahedas ahelas laborisse.
7. Mustrit saab toatemperatuuril (alla 30 ° C) salvestada kuni 24 tunniks
mustrivalikus või temperatuuril 2–8 ° C koguni 48 tundi alates mustrivaliku ajast.
2. etapp: mustri ettevalmistamine testimiseks:
1. Mustri ettevalmistamine peab toimuma labori BSL-2 astmekapis.
2. Kombineerige tampooniproov kenasti VTM-torusse (keeristage umbes 3-5 sekundit).
3. Lülitage 100 μL VITROS SARS-CoV-2 antigeeni ekstraheerimispuhver otse märgistatud uue mustriga tuubi.
4. Lisage ülaltoodud katsutisse 400 μL viiruse mustrit (et hoolitseda 1: nelja suhtega ekstraheerimispuhvri
ja mustri vahel).
Panbio™ COVID-19 Ag Rapid Test Device (Nasal) |
|||
| 41FK11 | Abbott | 25 Tests/Kit | EUR 128 |
|
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19 |
|||
COVID-19 IgG & IgM antibody |
|||
| GEN-50001-50tests | Ring Bio | 50 tests | EUR 388.8 |
|
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
|||
COVID-19 Nucleocapsid recombinant antigen |
|||
| 00221-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
|
Description: COVID-19 Nucleocapsid recombinant antigen |
|||
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) |
|||
| 3525-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) |
|||
| 3525-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Envelope Antibody (biotin) |
|||
| 3531-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
|||
SARS-CoV-2 (COVID-19) Envelope Antibody (biotin) |
|||
| 3531-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
|||
SARS-CoV-2 (COVID-19) Membrane Antibody (biotin) |
|||
| 9157-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
|||
SARS-CoV-2 (COVID-19) Membrane Antibody (biotin) |
|||
| 9157-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
|||
COVID-19 IgG/IgM Rapid Test Kit |
|||
| UNCOV-20 | UnScience | 20T/kit | EUR 186 |
|
Description: COVID-19 IgG/IgM Rapid Test (Serum/Plasma/Whole Blood) is a qualitative membrane-based immunoassay for the detection of COVID-19 antibodies in serum, plasma, or whole blood. This test consists of two test lines, an IgG line and an IgM line, which is pre-coated with two mouse anti-human monoclonal antibodies separately. During testing, the sample reacts with COVID-19 antigen-coated on conjugated pad. As the complex continues to travel up the strip, the anti-COVID-19 IgM antibodies are bound on the IgM line, and the anti-COVID-19 IgG antibodies are bound on the IgG line. The control(C)line appears when sample has flowed through the strip. The presence of anti-COVID-19 IgM and/or IgG will be indicated by a visible test line in the IgM and IgG region. To serve as a procedural control, the control line should always appear if the test procedure is performed properly and the reagents are working as intended. |
|||
COVID-19 Spike Protein a.a. 1000-12000 |
|||
| 00223-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
|
Description: COVID-19 Spike Protein a.a. 1000-12000 |
|||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
|||
| 9099-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
|||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
|||
| 9099-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
|||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
|||
| 9103-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
|||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
|||
| 9103-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
|||
SARS-CoV-2 (COVID-19) NSP7 Peptide |
|||
| 9155P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
| 9159P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
| 9161P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
| 9163P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
| 9167P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
| 9171P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
| 9173P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||